The 6th Cachexia Conference: An introduction to clinical and basic research in an exiting area

Journal of Cachexia, Sarcopenia and Muscle

Volumn 2, Issue 4, 2011, Pages 189-190

  von Haehling, Stephan ^a   Anker, Stefan D ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CACHEXIA; CLINICAL RESEARCH; EDITORIAL; MEDICAL SOCIETY; MUSCLE ATROPHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; WASTING SYNDROME;

EID: 84862834543     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-011-0048-0     Document Type: Editorial

References (7)

1. Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011; 3: 153-61.
2. Chen F, Lam R, Shaywitz D, Hendrickson RC, Opiteck GJ, Wishengrad D, et al. Evaluation of early biomarkers of muscle anabolic response to testosterone. J Cachexia Sarcopenia Muscle. 2011; 1: 45-56.
3. Rozentryt P, von Haehling S, Lainscak M, Nowak JU, Kalantar-Zadeh K, Polonski L, et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J Cachexia Sarcopenia Muscle. 2010; 1: 35-42.
4. von Haehling S, Lainscak M, Doehner W, Ponikowski P, Rosano G, Jordan J, et al. Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the studies investigating co-morbidities aggravating heart failure (SICA-HF). J Cachexia Sarcopenia Muscle. 2010; 2: 187-94.
5. Coats AJ, Srinivasan V, Surendran J, Chiramana H, Vangipuram SR, Bhatt NN, Jain M, Shah S, Ali IA, Fuang HG, Zailani M, Hassan M, Beadle J, Tilson J, Kirwan BA, Anker SD on behalf of the ACT-ONE Trial Investigators (2011) The ACT-ONE Trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachexia Sarcopenia Muscle. doi: 10. 1007/s13539-011-0046-2 (in press).
6. http://scholar. google. de (Accessed on 05 October, 2011).
7. von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia sSarcopenia Muscle. 2010; 1: 7-8.